OIM
TCRT icon

Oracle Investment Management’s Alaunos Therapeutics TCRT Stock Holding History

Oracle Investment Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-44
Closed -$36K – 22
2016
Q4 		$36K Hold
44
– – 0.01% 17
2016
Q3 		$38K Hold
44
– – 0.01% 17
2016
Q2 		$37K Hold
44
– – 0.01% 19
2016
Q1 		$49K Sell
44
-833
-95% -$853K 0.01% 20
2015
Q4 		$1.09M Sell
877
-18
-2% -$29.8K 0.19% 23
2015
Q3 		$1.21M Sell
895
-719
-45% -$1.19M 0.25% 23
2015
Q2 		$2.91M Buy
+1,614
New +$2.51M 0.35% 25

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Oracle Investment Management's TCRT Position: Q1 2017 in Review

Oracle Investment Management sold out of Alaunos Therapeutics (TCRT) in Q1 2017, closing a stake of 44 shares — an estimated $36K sold.

Oracle Investment Management first reported a position in TCRT in Q2 2015 and held it in 7 quarters. The position peaked at $2.91M in Q2 2015. 124 funds tracked by Wall St. Rank hold TCRT as of Q1 2017.

  • Oracle Investment Management reported no remaining Alaunos Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Oracle Investment Management sold 44 Alaunos Therapeutics shares in Q1 2017, an estimated $36K.
  • Oracle Investment Management first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 7 quarters.
  • Oracle Investment Management's Alaunos Therapeutics position peaked at $2.91M in Q2 2015.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2017.

Based on Oracle Investment Management's 13F filing for Q1 2017, filed 15 May 2017.